Antigen Characterized By Name Or Molecular Weight Patents (Class 424/156.1)
-
Patent number: 8273859Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.Type: GrantFiled: July 14, 2011Date of Patent: September 25, 2012Assignees: Perseus Proteomics Inc., The University of TokyoInventors: Hiroyuki Aburatani, Hiroko Iwanari, Isao Kohno
-
Patent number: 8263078Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.Type: GrantFiled: September 5, 2008Date of Patent: September 11, 2012Assignees: Inotek Pharmaceuticals Corporation, Yeda Research and Development Co., Ltd.Inventors: Nurit Rachamim, Andrew L. Salzman, Kanneganti Murthy
-
Patent number: 8258263Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).Type: GrantFiled: December 30, 2009Date of Patent: September 4, 2012Assignee: The Regents of the University of CaliforniaInventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
-
Publication number: 20120219560Abstract: The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and/or a de-N-acetylated sialic acid-modified cell surface protein.Type: ApplicationFiled: February 24, 2012Publication date: August 30, 2012Inventors: GREGORY R. MOE, Charles Paul Plested
-
Patent number: 8252267Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of diseases, including cancer. The invention provides novel splice products of human DKKL-1 gene. The present invention provides methods of using polynucleotides having the novel splice products of the human DKKL-1 sequences, their corresponding gene products and modulators of the DKKL-1 splice products for the detection, diagnosis, prevention and/or treatment of associated cancers.Type: GrantFiled: March 30, 2006Date of Patent: August 28, 2012Assignee: Sagres Discovery, Inc.Inventors: Albert Lai, Robert Booher
-
Patent number: 8236308Abstract: The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.Type: GrantFiled: October 10, 2006Date of Patent: August 7, 2012Assignee: Micromet AGInventors: Roman Kischel, Tobias Raum, Bernd Schlereth, Doris Rau, Ronny Cierpka, Peter Kufer
-
Patent number: 8216580Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.Type: GrantFiled: June 27, 2008Date of Patent: July 10, 2012Assignee: The Regents of the University of CaliforniaInventors: Roman Nawroth, Steven D. Rosen
-
Patent number: 8206711Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.Type: GrantFiled: December 2, 2009Date of Patent: June 26, 2012Assignees: Biogen Idec Inc., Genentech, Inc.Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
-
Publication number: 20120148598Abstract: Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.Type: ApplicationFiled: December 1, 2011Publication date: June 14, 2012Inventors: Soldano Ferrone, Xinhui Wang, Elvira Favoino, Ling Yu, Yangyang Wang
-
Patent number: 8192739Abstract: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.Type: GrantFiled: June 5, 2009Date of Patent: June 5, 2012Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Ken Chang, Sailaja S. Vanama, Edmund A. Rossi
-
Patent number: 8187594Abstract: The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.Type: GrantFiled: June 12, 2009Date of Patent: May 29, 2012Assignee: MacroGenics, Inc.Inventors: Jennie P. Mather, Penelope E. Roberts, Ronghao Li
-
Patent number: 8187593Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies.Type: GrantFiled: July 3, 2008Date of Patent: May 29, 2012Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri, Nadine Tuaillon, Ezio Bonvini
-
Patent number: 8182816Abstract: Disclosed are methods of treating subjects having cancers including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.Type: GrantFiled: November 11, 2010Date of Patent: May 22, 2012Assignees: Universidad Autonoma de Madrid, Consejo Superior de Investigaciones CientificasInventors: Francisco Sanchez-Madrid, Carlos-Martinez Alonso, David Sancho Madrid, Pablo Engel Rocamora, Enric Esplugues Artola, Javier Vega Ramos, Pilar Lauzurica Gomez
-
Patent number: 8182806Abstract: Synovial villi derived explants and related surgical tools used to repair or prevent damage to injured or diseased tissue, including connective tissue. The tools including a harvesting tool for selectively harvesting synovial villi from the joint of patient and a delivery tool having a bulbous end for delivering the synovial villi derived explants while reducing damage to surrounding tissue.Type: GrantFiled: August 2, 2010Date of Patent: May 22, 2012Inventor: Lanny L. Johnson
-
Patent number: 8173424Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: December 16, 2010Date of Patent: May 8, 2012Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 8168188Abstract: The present invention is directed to providing an antibody having greater reactivity with amylospheroid than with amyloid ? fibers, and the like. The aforementioned antibody includes an antibody having activity of inhibiting amylospheroid formation or activity of inhibiting neuronal cell death induced by amylospheroid. The antibody can be used for a therapeutic and/or preventive agent for Alzheimer's disease, or a screening thereof, a method and reagent for detecting individuals with Alzheimer's disease, and the like.Type: GrantFiled: August 11, 2005Date of Patent: May 1, 2012Assignee: Kyoto UniversityInventors: Minako Hoshi, Koji Naito, Shouji Ideno
-
Patent number: 8163287Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.Type: GrantFiled: July 19, 2006Date of Patent: April 24, 2012Assignee: Genentech, Inc.Inventors: Mark X. Sliwkowski, Stephen M. Kelsey
-
Publication number: 20120087916Abstract: The present invention relates to an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, and to the use thereof in medicine for the treatment of cancers, such as multiple myeloma.Type: ApplicationFiled: February 13, 2010Publication date: April 12, 2012Inventors: Bjorn Frendeus, Niina Veitonmaki, Titti Martinsson Niskanen
-
Publication number: 20120070430Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.Type: ApplicationFiled: April 22, 2010Publication date: March 22, 2012Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
-
Publication number: 20120052076Abstract: The present invention teaches anti-Trop-2 monoclonal antibodies with high affinity and able to recognize different regions of the Trop-2 molecule, and uses thereof in the treatment and diagnosis of tumors, such as for example endometrium, breast, head and neck, colon-rectum, stomach, lung, ovary, prostate, pancreas, kidney, cervix and bladder (urothelial) tumors.Type: ApplicationFiled: February 5, 2009Publication date: March 1, 2012Inventor: Saverio Alberti
-
Patent number: 8124738Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.Type: GrantFiled: September 26, 2006Date of Patent: February 28, 2012Assignee: Medarex, Inc.Inventors: Jonathan Alexander Terret, Li-sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
-
Patent number: 8124082Abstract: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.Type: GrantFiled: February 23, 2009Date of Patent: February 28, 2012Assignee: Genentech, Inc.Inventors: Sherman Fong, Mark S. Dennis
-
Publication number: 20120039797Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.Type: ApplicationFiled: September 26, 2011Publication date: February 16, 2012Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen
-
Patent number: 8114966Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.Type: GrantFiled: October 27, 2008Date of Patent: February 14, 2012Assignee: Forskarpatent I SYD ABInventors: Jan Nilsson, Roland Carlsson, Jenny Bengtsson, Leif Strandberg
-
Publication number: 20120034168Abstract: An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen-recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.Type: ApplicationFiled: April 22, 2009Publication date: February 9, 2012Applicants: Fondazione IRCCS "Istituto Nazionale dei Tumori", Universita' degli Studi di VeronaInventors: Marco Colombatti, Giulio Fracasso, Sara Cingarlini, Silvana Canevari, Mariangela Figini
-
Patent number: 8105596Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: March 15, 2011Date of Patent: January 31, 2012Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 8101179Abstract: A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The anti-CD20 monoclonal antibody is incorporated into chimeric anti-CD20 monoclonal antibodies in which the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody and the amino acid sequences of the constant regions of human immunoglobulin are fused. Also a humanized anti-CD20 monoclonal antibody is described which includes all of the variable region CDRs of the H chain of the anti-CD20 monoclonal antibody and all of the variable region CDRs of the L chain of the anti-CD20 monoclonal antibody and an amino acid sequence of human immunoglobulin. A nucleotide sequence encoding the amino acid sequence of the chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.Type: GrantFiled: March 31, 2006Date of Patent: January 24, 2012Assignee: Biomedics Inc.Inventors: Masanori Numazaki, Tetsuo Nakamura, Sadakazu Usuda, Eduardo A. Padlan
-
Publication number: 20120003232Abstract: Described is the use of antibodies which are directed against human cellular membrane antigens for the vaccination against cancer diseases.Type: ApplicationFiled: August 12, 2011Publication date: January 5, 2012Applicant: IGENEON KREBS-IMMUNTHERAPIE FORSCHUNGS-UND ENTWICKLUNGS-AGInventors: Helmut ECKERT, Hans Loibner
-
Patent number: 8088378Abstract: The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: July 15, 2008Date of Patent: January 3, 2012Assignee: Genetech Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8084020Abstract: The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous abortion, pregnancy, and cancer.Type: GrantFiled: May 1, 2003Date of Patent: December 27, 2011Assignee: Beth Israel Deaconess Medical CenterInventors: Mark A. Exley, Steven P. Balk, Simon C. Yue
-
Patent number: 8071323Abstract: Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided.Type: GrantFiled: April 6, 2007Date of Patent: December 6, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 8071101Abstract: The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis.Type: GrantFiled: November 2, 2006Date of Patent: December 6, 2011Assignee: Avaxia Biologics, Inc.Inventor: Barbara S. Fox
-
Publication number: 20110293608Abstract: AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.Type: ApplicationFiled: December 2, 2009Publication date: December 1, 2011Applicant: THE JOHNS HOPKINS UNIVERISTYInventors: Elizabeth Marion Jaffee, Lanqing Huang, Lei Zheng
-
Patent number: 8038996Abstract: Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided.Type: GrantFiled: March 10, 2005Date of Patent: October 18, 2011Assignee: University of ArizonaInventor: Daruka Mahadevan
-
Patent number: 8038994Abstract: Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.Type: GrantFiled: April 26, 2004Date of Patent: October 18, 2011Assignee: Quest Pharmatech Inc.Inventors: Birgit C. Schultes, Christopher F. Nicodemus, Antoine A. Noujaim, Ragupathy Madiyalakan
-
Patent number: 8021833Abstract: The importance of interaction between TSG101 and Vps28 in the release of HIV-1 and other viruses is disclosed. Suppressing or interfering in this interaction may inhibit HIV-1 virion release from infected cells. Agents that modulate this interaction include antibodies that bind to Vps28, polypeptides that bind to Vps28, and nucleic acids that may be used in gene therapy to interfere with the expression of wild type Vps28. Administration of such agents in vitro for screening and diagnostic purposes, and in vivo for diagnostic and therapeutic purposes, is disclosed.Type: GrantFiled: February 12, 2004Date of Patent: September 20, 2011Assignees: Functional Genetics, Inc., Johns Hopkins UniversityInventors: Xiao-Fang Yu, Bindong Liu, Limin Li
-
Patent number: 8013128Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: March 4, 2009Date of Patent: September 6, 2011Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 8007799Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.Type: GrantFiled: September 29, 2006Date of Patent: August 30, 2011Assignee: Genentech, Inc.Inventors: Nicholas Van Bruggen, Napoleone Ferrara
-
Patent number: 7982011Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.Type: GrantFiled: November 24, 2004Date of Patent: July 19, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Ira H. Pastan, Mitchell Ho, Sookhee Bang
-
Patent number: 7976838Abstract: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF?-inhibitor.Type: GrantFiled: March 20, 2008Date of Patent: July 12, 2011Assignee: Genentech, Inc.Inventor: Mark C. Benyunes
-
Publication number: 20110158902Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.Type: ApplicationFiled: January 24, 2011Publication date: June 30, 2011Applicant: NEOGENIX ONCOLOGY, INC.Inventors: Myron ARLEN, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
-
Publication number: 20110142848Abstract: A method for treating cancer includes treating a subject with an agent against beta-2-microglobulin; and treating the subject with radiation or a cancer therapeutic agent. The agent against beta-2-microglobulin includes anti-b2-M antibodies and miRNAs.Type: ApplicationFiled: August 7, 2009Publication date: June 16, 2011Inventors: Leland W.K. Chung, Sajni Josson, Wen-Chin Huang, Haiyen E. Zhau
-
Publication number: 20110129416Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: ApplicationFiled: January 24, 2011Publication date: June 2, 2011Applicant: NEOGENIX ONCOLOGY, INC.Inventors: J. Andrew BRISTOL, Judith A. Kantor
-
Publication number: 20110129482Abstract: In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.Type: ApplicationFiled: November 23, 2010Publication date: June 2, 2011Applicant: VASGENE THERAPEUTICS, INC.Inventors: Valery Krasnoperov, Sergey Zozulya, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill
-
Patent number: 7951917Abstract: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide.Type: GrantFiled: March 7, 2000Date of Patent: May 31, 2011Assignee: Genentech, Inc.Inventors: W. Robert Arathoon, Paul J. Carter, Anne M. Merchant, Leonard G. Presta
-
Publication number: 20110110955Abstract: A method for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R?2 in the subject. A composition for stimulating a immune response against IL-13R?2 in a subject having or at risk for developing a disease having cells expressing IL-13R?2 includes an isolated agent that can stimulate immune response against IL-13?2.Type: ApplicationFiled: September 20, 2010Publication date: May 12, 2011Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: Waldemar Debinski, Neil Christensen, Akiva Mintz
-
Patent number: 7939074Abstract: A combination of an anti-Ep-CAM antibody with a chemotherapeutic agent that is capable of arresting Ep-CAM antigen expressing cells in S or G2/M.Type: GrantFiled: January 8, 2010Date of Patent: May 10, 2011Assignee: GlaxoSmithKline LLCInventors: Vincent C. Knick, Julie Beth Stimmel, Linda M. Thurmond
-
Patent number: 7939073Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: October 21, 2005Date of Patent: May 10, 2011Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Publication number: 20110104147Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.Type: ApplicationFiled: April 22, 2010Publication date: May 5, 2011Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Publication number: 20110097338Abstract: The invention relates to the use of substances to increase the sensitivity of tumor cells to treatment with radiation and/or chemotherapy. This is accomplished through the use of substances which block or limit the function of the PINCH-1 protein for sensitization of tumor cells to radiation and/or chemotherapy.Type: ApplicationFiled: February 20, 2009Publication date: April 28, 2011Applicant: TECHNISCHE UNIVERSITAET DRESDENInventors: Nils Cordes, Michael Baumann, Iris Eke, Ulrike Koch, Veit Sandfort